PMID: 2118417Sep 1, 1990Paper

Leuprolide with and without flutamide in advanced prostate cancer

Cancer
E D CrawfordF A Dorr

Abstract

In a randomized, double-blind trial for metastatic prostate cancer (Stage D2), 603 men received leuprolide, a gonadotropin-releasing hormone analog that inhibits the release of gonadotropins, coupled with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. The 303 men receiving androgen blockade with leuprolide and flutamide demonstrated a longer progression-free survival (16.9 vs. 13.9 months, P = 0.039) and an increased median length of survival (35.0 vs. 27.9 months, P = 0.035). In the subgroup of men with minimal disease and good performance status, the advantages of maximal androgen blockade were more pronounced. It is concluded that combined androgen blockade with leuprolide and flutamide was more effective than leuprolide alone for patients with metastatic cancer of the prostate. The therapeutic benefits, although greatest in patients with minimum disease, need to be evaluated in a prospective, randomized fashion in trials specifically designed for men with minimal disease and good performance status. Exploratory analyses using the black race as an explanatory variable were also performed. Black race is associated with shorter survival times and is also ass...Continue Reading

References

Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A EisenbergerM A Friedman
Aug 1, 1987·Endocrine Reviews·G R CunhaY Sugimura
Nov 15, 1984·The New England Journal of Medicine·UNKNOWN Leuprolide Study Group
Jun 1, 1983·British Journal of Urology·C R Woodhouse, E P O'Donoghue
Apr 1, 1980·Cancer·William W ScottPatrick C Walsh

❮ Previous
Next ❯

Citations

Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Eric J Small
Dec 15, 1993·Cancer·S SuciuL Denis
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M RoachP R Carroll
Jan 5, 2000·Seminars in Surgical Oncology·M K Brawer
Jun 28, 2006·Prostate Cancer and Prostatic Diseases·N D JamesC Luscombe
Nov 9, 2000·BJU International·D HroudaA G Dalgleish
May 5, 2000·The Cochrane Database of Systematic Reviews·B SchmittT Wilt
May 21, 2010·American Journal of Men's Health·Gayathri SridharJohn D Roberts
Nov 7, 2006·The Journal of Urology·Charles J Ryan, Eric J Small
Oct 22, 2008·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Kelly K CurtisMichael K Gornet
Sep 7, 2007·Cancer Immunology, Immunotherapy : CII·M-C LabartheM A Whelan
Jun 1, 1994·Postgraduate Medicine·Craig A Winkel
Nov 7, 1998·Cancer Treatment Reviews·A J Dowling, I F Tannock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.